Chemistry:XW10508
XW10508 is an orally active prodrug of esketamine, an NMDA receptor antagonist, which is under development for the treatment of major depressive disorder and chronic pain.[1][2][3][4] It is taken by mouth.[1][3][4]
The drug is a novel esketamine analogue and conjugate that acts as a prodrug of esketamine.[4] Esketamine, and by extension XW10508, is an NMDA receptor antagonist and indirect AMPA receptor activator.[1][5] XW10508 is being developed as once-daily orally administered extended-release and immediate-release formulations with misuse resistance.[1][4]
As of August 2024, XW10508 is in phase 2 clinical trials for major depressive disorder and is in phase 1 clinical trials for chronic pain.[1][2][3] However, no recent development has been reported for these indications.[1] The drug is being developed by XWPharma, which was previously known as XW Laboratories.[1][2][3] It is being developed in Australia.[1][3] The chemical structure of XW10508 does not yet seem to have been disclosed.[1]
See also
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 "XW 10508". 28 August 2024. https://adisinsight.springer.com/drugs/800060585.
- ↑ 2.0 2.1 2.2 "Delving into the Latest Updates on XW-10508 with Synapse". 1 November 2024. https://synapse.patsnap.com/drug/e89fc2fe9e8c4313be93642155d5c27a.
- ↑ 3.0 3.1 3.2 3.3 3.4 "XW-10508 Drug Profile". 13 April 2024. https://pryzm.ozmosi.com/product/23345. "XW10508 is an internally discovered, investigational, orally bioavailable, once-daily glutamatergic providing NMDA receptor inhibition and AMPA receptor activation in development for the intended treatment of MDD and chronic pain."
- ↑ 4.0 4.1 4.2 4.3 "XWPharma Initiates First-in-Human Studies of XW10508, in Development for Fast-acting Relief of Treatment-Resistant Depression and Chronic Pain". GlobeNewswire News Room (Press release). 8 September 2021. Retrieved 2 November 2024.
- ↑ "Ketamine: A tale of two enantiomers". J Psychopharmacol 35 (2): 109–123. February 2021. doi:10.1177/0269881120959644. PMID 33155503.
External links
